NCT07263074 Considering alloHCT: Opportunities for Patient Reflection During Decision-Making Via Digital Stories
| NCT ID | NCT07263074 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Rochester |
| Condition | Myeloid Malignancy |
| Study Type | INTERVENTIONAL |
| Enrollment | 120 participants |
| Start Date | 2026-01-15 |
| Primary Completion | 2028-06-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 120 participants in total. It began in 2026-01-15 with a primary completion date of 2028-06-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This is a two-arm pilot randomized trial that assesses the feasibility and preliminary efficacy of a digital story and values clarification intervention (Considering alloHCT: Opportunities for Patient Reflection During Decision-Making via Digital Stories \[CHORDS\]) compared to usual care among patients with myeloid cancers considering allogeneic hematopoietic cell transplantation (alloHCT).
Eligibility Criteria
Patients Inclusion criteria: 1. Age \>21 years old 2. Diagnosis of myeloid cancer (AML, MDS, myelofibrosis, CML, or MDS/MPN) 3. Being considered for alloHCT 4. Able to provide informed consent 5. Able to speak English. The reason for this is because the digital stories have been created in the English language and their multimedia form cannot easily be translated. Exclusion criteria 1) Patients with psychiatric or cognitive conditions which the hematologist believes prohibits informed consent or compliance with study procedures Caregivers Inclusion criteria: 1. Age \>18 years old 2. Selected by the patient when asked if there is a "family member, partner, friend or caregiver with whom you discuss or who can be helpful in health-related matters." 3. Caregiver may be paid/professional or informal caregiver 4. Able to provide informed consent 5. Able to speak English Exclusion Criteria: 1\) None Hematologists Inclusion criteria: 1\) Hematologists of the patients who agree to enroll on the study who are part of Wilmot Cancer Institute. Exclusion criteria 1\) None
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07263074 clinical trial?
This trial is open to participants of all sexes, aged 21 Years or older, studying Myeloid Malignancy. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07263074 currently recruiting?
Yes, NCT07263074 is actively recruiting participants. Contact the research team at rachel_rodenbach@urmc.rochester.edu for enrollment information.
Where is the NCT07263074 trial being conducted?
This trial is being conducted at Rochester, United States.
Who is sponsoring the NCT07263074 clinical trial?
NCT07263074 is sponsored by University of Rochester. The trial plans to enroll 120 participants.